Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas

被引:64
作者
Hall, KL
Teneriello, MG
Taylor, RR
Lemon, S
Ebina, M
Linnoila, RI
Norris, H
Park, RC
Birrer, MJ
机构
[1] NCI, BIOMARKERS & PREVENT RES BRANCH, DIV CLIN SCI, ROCKVILLE, MD 20850 USA
[2] BROOKE ARMY MED CTR, DEPT OBSTET & GYNECOL GYNECOL ONCOL, FT SAM HOUSTON, TX 78234 USA
[3] NATL NAVAL MED CTR, BETHESDA, MD 20889 USA
[4] WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA
关键词
D O I
10.1006/gyno.1997.4653
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Uterine sarcomas are unusual neoplasms of the female genital tract whose molecular etiology is largely unknown. We examined 20 leiomyomas as well as 23 uterine leiomyosarcomas for the presence of mutations in the Ki-ras and p53 genes, and overexpression of the MDM2 gene. Codons 12, 13, and 61 from the Ki-ras gene were characterized for the presence of mutations by restriction enzyme polymorphisms using mismatched primers and nucleic acid sequencing as appropriate, Activated Ki-ras genes were identified in 3/20 leiomyomas and 0/23 leiomyosarcomas. The p53 gene was analyzed by SSCP, nucleic acid sequencing, and immunohistochemical staining, None of 20 leiomyomas and 6/23 leiomyosarcomas exhibited p53 abnormalities. The SSCP/sequencing results did not consistently correlate with the IHC staining. MDM2 overexpression occurred in 0/20 leiomyomas and 3/23 sarcomas. Clinical correlation suggested that tumors with p53 mutations have a higher histologic grade or stage at presentation, We conclude that leiomyomas and leiomyosarcomas have different patterns of molecular alterations and are separate biologic entities. In addition, p53 and MDM2 overexpression may play a role in the development of a subset of leiomyosarcomas. (C) 1997 Academic Press.
引用
收藏
页码:330 / 335
页数:6
相关论文
共 20 条
  • [1] BODNER SM, 1992, ONCOGENE, V7, P743
  • [2] BOS JL, 1989, CANCER RES, V49, P4682
  • [3] P53 ALTERATIONS IN UTERINE LEIOMYOSARCOMAS VERSUS LEIOMYOMAS
    DEVOS, S
    WILCZYNSKI, SP
    FLEISCHHACKER, M
    KOEFFLER, P
    [J]. GYNECOLOGIC ONCOLOGY, 1994, 54 (02) : 205 - 208
  • [4] EBINA M, 1994, CANCER RES, V54, P2496
  • [5] GREENBLATT MS, 1994, CANCER RES, V54, P4855
  • [6] HACKER NF, 1994, PRACTICAL GYNECOLOGI, P314
  • [7] P53 MUTATIONS IN HUMAN CANCERS
    HOLLSTEIN, M
    SIDRANSKY, D
    VOGELSTEIN, B
    HARRIS, CC
    [J]. SCIENCE, 1991, 253 (5015) : 49 - 53
  • [8] P53 IMMUNOREACTIVITY AND MUTATION OF THE P53 GENE IN SMOOTH-MUSCLE TUMORS OF THE UTERINE CORPUS
    JEFFERS, MD
    FARQUHARSON, MA
    RICHMOND, JA
    MCNICOL, AM
    [J]. JOURNAL OF PATHOLOGY, 1995, 177 (01) : 65 - 70
  • [9] LIU FS, 1994, OBSTET GYNECOL, V83, P118
  • [10] MARKS JR, 1991, CANCER RES, V51, P2979